Gait analysis in three different 6-hydroxydopamine rat models of Parkinson's disease

被引:48
|
作者
Zhou, Ming [1 ]
Zhang, Wangming [1 ]
Chang, Jingyu [2 ]
Wang, Jun [1 ]
Zheng, Weixin [1 ]
Yang, Yong [1 ]
Wen, Peng [1 ]
Li, Min [1 ]
Xiao, Hu [1 ]
机构
[1] Southern Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China
[2] Neurosci Res Inst North Carolina, Winston Salem, NC USA
基金
中国国家自然科学基金;
关键词
Parkinson's disease; Gait; CatWalk; 6-Hydroxydopamine; Neurochemical correlation; STIMULATION; LOCOMOTION; INITIATION; DISORDERS; MOVEMENT; 6-OHDA; SPEED;
D O I
10.1016/j.neulet.2014.10.032
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gait deficits are important clinical symptoms of Parkinson's disease (PD) but are rarely studied. In this study we made three different rat PD models by administration of 6-hydroxydopamine into caudate putamen (CPU), medial forebrain bundle (MFB) and substantia nigra compact (SNC). We evaluated the gait changes in these models by using a computer-assisted CatWalk system. Correlations of gait parameters with tyrosine hydroxylase protein levels in the CPU and SNC were also investigated. The gait readouts were significantly impaired in both the MFB and SNC groups. However, the MFB group showed a more pronounced impairment than the SNC group. In contrast, only mild and incomplete gait impairment occurred in the CPU group. In addition, some gait parameters demonstrated close correlation with the protein levels of TH. This paper suggests that the 6-hydroxydopamine-induced MFB model is more propitious to study gait dysfunction than the other two models and the CatWalk system can provide reliable and objective criteria to stratify gait changes arising from 6-hydroxydopamine lesioned rats. These findings may hold promise in the study of PD disease progression and new therapeutic methods. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:184 / 189
页数:6
相关论文
共 50 条
  • [1] The 6-hydroxydopamine Rat Model of Parkinson's Disease
    Guimaraes, Rayanne Poletti
    Ribeiro, Danilo Leandro
    dos Santos, Keila Bariotto
    Godoy, Livea Dornela
    Correa, Mirella Rosine
    Padovan-Neto, Fernando Eduardo
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (176):
  • [2] The 6-hydroxydopamine model of Parkinson's disease
    Simola, Nicola
    Morelli, Micaela
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2007, 11 (3-4) : 151 - 167
  • [3] Respiratory activity in the 6-hydroxydopamine model of Parkinson's disease in the rat
    Budzinska, Krystyna
    Andrzejewski, Kryspin
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2014, 74 (01) : 67 - 81
  • [4] The 6-Hydroxydopamine model of parkinson’s disease
    Nicola Simola
    Micaela Morelli
    Anna R. Carta
    Neurotoxicity Research, 2007, 11 : 151 - 167
  • [5] Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease
    Henning, Jeannette
    Strauss, Ulf
    Wree, Andreas
    Gimsa, Jan
    Rolfs, Arndt
    Benecke, Reiner
    Gimsa, Ulrike
    NEUROSCIENCE RESEARCH, 2008, 62 (04) : 246 - 253
  • [6] Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson's disease
    Li, Jia
    Sun, Yajuan
    Chen, Jiajun
    GENES & GENETIC SYSTEMS, 2019, 94 (02) : 61 - 69
  • [7] Effects of puerarin on gait disturbance in a 6-hydroxydopamine mouse model of Parkinson's disease
    Kim, Na-Hyun
    Goto, Yukiori
    Lee, Young-A
    PHARMACOLOGICAL REPORTS, 2025, 77 (01) : 247 - 259
  • [8] Characterization of the gastrointestinal dysfunction in the 6-hydroxydopamine rat model of Parkinson's disease
    Chai, X.
    Diwakarla, S.
    Pustovit, R.
    McQuade, R.
    Di Natale, M.
    Ermine, C.
    Parish, C.
    Finkelstein, D.
    Furness, J.
    MOVEMENT DISORDERS, 2019, 34 : S629 - S629
  • [9] Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP
    Grünblatt, E
    Mandel, S
    Youdim, MBH
    REACTIVE OXYGEN SPECIES: FROM RADIATION TO MOLECULAR BIOLOGY: A FESTSCHRIFT IN HONOR OF DANIEL L GILBERT, 2000, 899 : 262 - 273
  • [10] Therapeutic potential of bromelain in 6-hydroxydopamine rat model of parkinson's disease
    Cicek, B.
    Gul, M.
    Taghizadehghalehjoughi, A.
    Okkay, U.
    Yildirim, S.
    Okkay, I. F.
    Ertugrul, M. S.
    Aydin, I. C.
    Bayram, C.
    Arslan, Y. K.
    Hacimuftuoglu, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S438 - S439